Study of Molecular Mechanism of the Interaction Between MEK1/2 and Trametinib with Docking and Molecular Dynamic Simulation
- 21 November 2018
- journal article
- research article
- Published by Springer Nature in Interdisciplinary Sciences: Computational Life Sciences
- Vol. 11 (1) , 115-124
Abstract
Trametinib was endorsed by the FDA in 2013 as a single agent for adult melanoma patients. Trametinib inhibits cell growth and proliferation in multiple tumor xenografts by preventing RAF phosphorylation of MEK and thus restricting accumulation of activated MEK. In this study, the focus of investigation was the mechanism of the interaction between trametinib and MEK1/2 via computational simulation. To specify the best interaction site of inhibitor with MEK1/2 based on the interaction energy ranking, first we performed a docking and then we studied the interactions of the ATP-bound MEK with trametinib, with RAF and the complex of the ATP-bound MEK–trametinib with RAF via molecular dynamic simulations. The results showed that trametinib inactivates the enzyme by bonding to a group of amino acids including Lys97/101, SER218/216, Asp208/212, and Met143/147 in MEK1/2. By bonding to the essential amino acids, trametinib inhibits the activity of the enzyme. All in all, the acquired results can be of great use in designing new inhibitors.Keywords
This publication has 23 references indexed in Scilit:
- Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479Bioorganic & Medicinal Chemistry Letters, 2014
- Gold nanoparticle shape effects on human serum albumin corona interface: a molecular dynamic studyJournal of Nanoparticle Research, 2014
- MEK1/2 inhibitors in the treatment of gynecologic malignanciesGynecologic Oncology, 2014
- Comparison of amino acids interaction with gold nanoparticleAmino Acids, 2013
- Trametinib: First Global ApprovalDrugs, 2013
- Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivoInternational Journal of Oncology, 2011
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway InhibitionClinical Cancer Research, 2011
- Pathological roles of MAPK signaling pathways in human diseasesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
- MAP kinase signalling pathways in cancerOncogene, 2007
- Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibitionNature Structural & Molecular Biology, 2004